Lumos Diagnostics Holdings (ASX:LDX) Accounts Receivable : A$2.38 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Lumos Diagnostics Holdings's accounts receivables for the quarter that ended in Dec. 2023 was A$2.38 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Lumos Diagnostics Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 105.12.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Lumos Diagnostics Holdings's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was A$-0.03.

Lumos Diagnostics Holdings Accounts Receivable Historical Data

The historical data trend for Lumos Diagnostics Holdings's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Accounts Receivable Chart

Lumos Diagnostics Holdings Annual Data

Trend

Jun22

Jun23

Accounts Receivable

5.90

4.77

Lumos Diagnostics Holdings Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Receivable	Get a 7-Day Free Trial			2.82	5.90	2.34	4.77	2.38

Lumos Diagnostics Holdings Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Lumos Diagnostics Holdings Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Lumos Diagnostics Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.38	/	4.132	*	91
=	105.12

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Lumos Diagnostics Holdings's accounts receivable are only considered to be worth 75% of book value:

Lumos Diagnostics Holdings's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.06	+	0.75 * 2.38	+	0.5 * 1.999	-	20.655
-	0	-	0)	/	481.3
=	-0.03

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Lumos Diagnostics Holdings Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings (ASX:LDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

LDXHF:USA

Address

2724 Loker Ave West, Carlsbad, CA, USA, 92010

Website

https://www.lumosdiagnostics.com

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines